Optic Neuropathy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Optic Neuropathy - Pipeline Review, H2 2016

Optic Neuropathy - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Optic Neuropathy - Pipeline Review, H2 2016
Published Aug 24, 2016
59 pages — Published Aug 24, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Optic Neuropathy - Pipeline Review, H2 2016, provides an overview of the Optic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy
- The report reviews pipeline therapeutics for Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Optic Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Optic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Optic Neuropathy


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication th

  
Source:
Document ID
GMDHC8377IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Optic Neuropathy Overview71
Therapeutics Development82
  Pipeline Products for Optic Neuropathy Overview81
  Pipeline Products for Optic Neuropathy Comparative Analysis91
Optic Neuropathy Therapeutics under Development by Companies101
Optic Neuropathy Therapeutics under Investigation by Universities/Institutes111
Optic Neuropathy Pipeline Products Glance123
  Late Stage Products121
  Clinical Stage Products131
  Early Stage Products141
Optic Neuropathy Products under Development by Companies151
Optic Neuropathy Products under Investigation by Universities/Institutes161
Optic Neuropathy Companies Involved in Therapeutics Development177
  Amgen Inc.171
  BioAxone BioSciences, Inc.181
  Inotek Pharmaceuticals Corporation191
  Ironwood Pharmaceuticals, Inc.201
  PharmatrophiX, Inc.211
  Quark Pharmaceuticals, Inc.221
  Regenera Pharma Ltd.231
Optic Neuropathy Therapeutics Assessment249
  Assessment by Monotherapy Products241
  Assessment by Target252
  Assessment by Mechanism of Action272
  Assessment by Route of Administration292
  Assessment by Molecule Type312
Drug Profiles3321
  BA-240 Drug Profile331
  IWP-953 Drug Profile341
  LM-22A4 Drug Profile351
  Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy Drug Profile361
  NT-501 Drug Profile373
  QPI-1007 Drug Profile402
  RPh-201 Drug Profile422
  Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy Drug Profile441
  Small Molecules for CNS Disorders and Ophthalmology Drug Profile451
  Small Molecules for Neurological and Ophthalmological Diseases Drug Profile461
  Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders Drug Profile472
  Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy Drug Profile491
  trabodenoson Drug Profile503
  WSTB-1 Drug Profile531
Optic Neuropathy Dormant Projects541
Optic Neuropathy Product Development Milestones553
  Featured News &Press Releases551
    Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant551
    Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India551
    Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting561
    Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications561
    Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION571
    Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy571
    Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies571
Appendix582
  Methodology581
  Coverage581
  Secondary Research581
  Primary Research581
  Expert Panel Validation581
  Contact Us581
  Disclaimer591

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Optic Neuropathy - Pipeline Review, H2 2016" Aug 24, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Optic-Neuropathy-Pipeline-Review-H2-2016-2088-16419>
  
APA:
Global Markets Direct - Market Research. (2016). Optic Neuropathy - Pipeline Review, H2 2016 Aug 24, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Optic-Neuropathy-Pipeline-Review-H2-2016-2088-16419>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.